Important Dates

• Abstracts should be submitted online.
• Once the submission is completed, a confirmation e-mail will be sent automatically. If you do not receive the confirmation e-mail within 24 hours after submission, please contact the Congress Secretariat.
• Abstract number will be generated automatically when an abstract is submitted.
• For changes, withdrawal or additional submission, please log in to the system using your ID and password from ” Abstract Submission” button at the bottom of this page.
• If you have any questions, please contact the Congress Secretariat. （ E-mail:endai-jsprs68@convention.co.jp）

Responsibilities of the Presenting Author

• The first author listed for each abstract serves as the presenting author and as the primary contact for all correspondence regarding the abstract.
• The presenting author must be one of the co-authors listed on the submitted abstract.
• The presenting author is responsible for ensuring that all authors have read the abstract and agreed to be co-authors.

Type of Presentation

Each speaker will have 10 minutes for presentation. Please time your talk for 8 minutes, and 2 minutes for questions and answers.

*Type of presentation in the JSPRS2025 is only ORAL PRESENTATION.

Abstract Submission Instruction

Your abstract must include:

• Your Name (Name of the First Author)
• Name(s) of Affiliation (This will be printed in the Program Book)
• Name(s) and Affiliation(s) for Co-Authors (up to 8 people)
• Contact E-mail Address
• Title of Abstract (100 one-byte characters)
  The abstract title should be brief and clearly indicate the nature of the presentation. Do not put a period at the end of the title.
• Abstract Body (within 1,600 one-byte characters)
• No tables or diagrams should be included.
• Category
  Please select 1 or 2 Categories to your abstract. (Categories will not be printed in the Program Book; they will be used as a reference for peer review.)

Category

Abstract Review and Selection Process

• After the submission deadline, all completed and eligible abstracts will be made available to the Organizing Review Committees for blinded review and scoring, and final decisions will be made in the end of January 2025.
• Incomplete abstracts will not be reviewed.
• All abstracts submitted will be considered eligible for one presentation (ORAL PRESENTATION).

Acceptance / Rejection Notification

• Notification regarding acceptance or rejection of abstracts will be sent to the first (presenting) author by the beginning of January 2025 by e-mail; consequently, an accurate e-mail address is critical. Rejection notifications will also be sent at that time.
• If you have not received the e-mail, please contact Congress Secretariat shown at the bottom of this page.

Conflict-Of-Interest (COI) Disclosure Policies

• Conflict-Of-Interest (COI) Policy requires disclosure of any financial or other interest that might be construed as resulting in an actual, potential, or apparent conflict.
• Please disclose any relationships or circumstances that might affect or appear to affect the research presented. These relationships include you or any individual with whom you directly share income.
• All authors and co-authors are required to provide any relevant information concerning personal or professional circumstances and relationships that might reasonably be expected to affect the author’s view on the presentation; including relationships with pharmaceutical companies, or other companies whose products or services are related to the subject matter of the presentation topic. If no relevant relationships exist, this must be stated as well.